Protagenic Therapeutics, Inc.\new APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Protagenic Therapeutics, Inc.\new (PTIX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $67.01 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-19
- Protagenic Therapeutics, Inc.\new apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $67.01K, a 46.44% decline year-over-year.
- Protagenic Therapeutics, Inc.\new apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $95.94K.
- Protagenic Therapeutics, Inc.\new apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $105.87K, a 57.72% decline year-over-year.
- Protagenic Therapeutics, Inc.\new apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $125.13K, a 52.86% decline year-over-year.
- Protagenic Therapeutics, Inc.\new apic, share-based payment arrangement, increase for cost recognition for fiscal 2026 was $418.59K.
- Protagenic Therapeutics, Inc.\new apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $923.14K, a 38.44% increase from fiscal 2023.
- Protagenic Therapeutics, Inc.\new apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $666.83K, a 21.02% decline from fiscal 2022.
- Protagenic Therapeutics, Inc.\new apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $844.25K, a 44.41% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 24 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $67.01K 10-Q · filed 2026-08-19 | |||||
| 2026-03-31 | $418.59K 10-K · filed 2026-08-14 | |||||
| 2025-12-31 | $95.94K 10-Q · filed 2026-03-09 | $201.81K derived: sum of 2 quarters · filed 2026-03-09 | $326.94K derived: sum of 3 quarters · filed 2026-08-19 | $562.95K derived: sum of 4 quarters · filed 2026-08-19 | ||
| 2025-09-30 | $105.87K 10-Q · filed 2026-03-09 | $231.00K derived: sum of 2 quarters · filed 2026-08-19 | $467.01K derived: sum of 3 quarters · filed 2026-08-19 | |||
| 2025-06-30 | $125.13K 10-Q · filed 2026-08-19 | $361.14K derived: sum of 2 quarters · filed 2026-08-19 | ||||
| 2025-03-31 | $236.01K 10-Q · filed 2025-05-13 | |||||
| 2024-12-31 | $923.14K 10-K · filed 2025-03-31 | |||||
| 2024-09-30 | $250.40K 10-Q · filed 2024-11-14 | $515.84K derived: sum of 2 quarters · filed 2024-11-14 | $677.70K derived: sum of 3 quarters · filed 2025-05-13 | |||
| 2024-06-30 | $265.44K 10-Q · filed 2024-11-14 | $427.30K derived: sum of 2 quarters · filed 2025-05-13 | ||||
| 2024-03-31 | $161.86K 10-Q · filed 2025-05-13 | |||||
| 2023-12-31 | $666.83K 10-K · filed 2025-03-31 | |||||
| 2023-09-30 | $166.71K 10-Q · filed 2024-11-14 | $333.41K derived: sum of 2 quarters · filed 2024-11-14 | $500.12K derived: sum of 3 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $166.71K 10-Q · filed 2024-11-14 | $333.41K derived: sum of 2 quarters · filed 2024-11-14 | ||||
| 2023-03-31 | $166.71K 10-Q · filed 2024-11-14 | |||||
| 2022-12-31 | $844.25K 10-K/A · filed 2024-05-14 | |||||
| 2022-09-30 | $214.68K 10-Q · filed 2023-11-14 | $430.21K derived: sum of 2 quarters · filed 2023-11-14 | $645.56K derived: sum of 3 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $215.53K 10-Q · filed 2023-11-14 | $430.88K derived: sum of 2 quarters · filed 2023-11-14 | ||||
| 2022-03-31 | $215.35K 10-Q · filed 2023-11-14 | $235.78K 10-Q · filed 2022-05-13 | ||||
| 2021-12-31 | $1.52M 10-K · filed 2023-03-31 | |||||
| 2021-09-30 | $231.65K 10-Q · filed 2022-11-14 | $954.62K derived: sum of 2 quarters · filed 2022-11-14 | $1.30M derived: sum of 3 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $722.97K 10-Q · filed 2022-11-14 | $1.07M derived: sum of 2 quarters · filed 2022-11-14 | ||||
| 2021-03-31 | $345.98K 10-Q · filed 2022-11-14 | |||||
| 2020-12-31 | $1.43M 10-K · filed 2022-04-07 | |||||
| 2020-09-30 | $458.57K 10-Q · filed 2021-11-15 | $762.72K derived: sum of 2 quarters · filed 2021-11-15 | $1.12M derived: sum of 3 quarters · filed 2021-11-15 | |||
| 2020-06-30 | $304.15K 10-Q · filed 2021-11-15 | $664.58K derived: sum of 2 quarters · filed 2021-11-15 | ||||
| 2020-03-31 | $360.44K 10-Q · filed 2021-11-15 | |||||
| 2019-12-31 | $797.76K 10-K · filed 2021-03-25 | |||||
| 2019-09-30 | $139.07K 10-Q · filed 2020-11-16 | $399.63K derived: sum of 2 quarters · filed 2020-11-16 | $850.77K derived: sum of 3 quarters · filed 2020-11-16 | |||
| 2019-06-30 | $260.56K 10-Q · filed 2020-11-16 | $711.70K derived: sum of 2 quarters · filed 2020-11-16 | ||||
| 2019-03-31 | $451.14K 10-Q · filed 2020-11-16 | |||||
| 2018-12-31 | $1.13M 10-K · filed 2020-04-29 | |||||
| 2018-09-30 | $263.15K 10-Q · filed 2019-11-14 | $526.30K derived: sum of 2 quarters · filed 2019-11-14 | $870.94K derived: sum of 3 quarters · filed 2019-11-14 | |||
| 2018-06-30 | $263.15K 10-Q · filed 2019-11-14 | $607.79K derived: sum of 2 quarters · filed 2019-11-14 | ||||
| 2018-03-31 | $344.65K 10-Q · filed 2019-11-14 | |||||
| 2017-12-31 | $888.28K 10-K · filed 2019-03-29 | |||||
| 2017-03-31 | $355.34K 10-Q · filed 2017-05-15 | $450.90K derived: sum of 2 quarters · filed 2018-04-02 | $661.61K derived: sum of 3 quarters · filed 2018-04-02 | $798.56K derived: sum of 4 quarters · filed 2018-04-02 | ||
| 2016-12-31 | $95.57K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $306.27K derived: sum of 2 quarters · filed 2018-04-02 | $443.23K derived: sum of 3 quarters · filed 2018-04-02 | $546.13K 10-K · filed 2018-04-02 | ||
| 2016-09-30 | $210.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-17 | $347.66K derived: sum of 2 quarters · filed 2016-11-17 | $450.57K 10-Q · filed 2016-11-17 | |||
| 2016-06-30 | $136.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $239.87K 10-Q · filed 2016-08-15 | ||||
| 2016-03-31 | $102.91K 10-Q · filed 2016-07-25 | |||||
| 2015-12-31 | $478.63K 8-K/A · filed 2016-07-12 | $477.87K 10-K/A · filed 2017-05-08 | ||||
| 2014-12-31 | $85.17K 8-K/A · filed 2016-07-12 | |||||
| 2014-06-30 | $275.00K 10-K · filed 2014-10-14 | |||||
| 2011-09-30 | $33.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-14 | $285.00K 10-Q · filed 2011-11-14 | ||||
| 2011-06-30 | $252.00K 10-Q/A · filed 2011-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |